Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : ¿¬±¸¼Ò ´º½º
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [¾à¾÷½Å¹®] ¡°Äڷγª19 Ä¡·áÁ¦¡¤¹é½Å, °æÀïÁ¦Ç° ºñ±³¿ìÀ§ È®º¸ Çʼö¡±
³»   ¿ë

¡°Äڷγª19 Ä¡·áÁ¦¡¤¹é½Å, °æÀïÁ¦Ç° ºñ±³¿ìÀ§ È®º¸ Çʼö¡±

ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ÀÓÀ翵 ½ÇÀå, Á¤Ã¥Æ÷·³¼­ Á¤ºÎ Àû±Ø Áö¿ø µî ÁÖ¹®

±èÁ¤ÀÏ ±âÀÚ | jikim@yakup.com  

Äڷγª19 Ä¡·áÁ¦ ¹× ¹é½Å °³¹ß»çµéÀº Àü ¼¼°èÀûÀ¸·Î ´Ù¼öÀÇ °æÀï Á¦Ç°ÀÌ Á¸ÀçÇÏ´Â ¸¸Å­ ºñ±³¿ìÀ§ È®º¸ °úÁ¤ µî ¸é¹ÐÇÑ °³¹ßÀü·«À» °®Ãç¾ß Çϸç, À̸¦ µÞ¹ÞħÇÒ Á¤ºÎÀÇ Àû±ØÀûÀÎ Áö¿øÀÌ ÇÊ¿äÇÏ´Ù´Â ÁöÀûÀÌ´Ù.

ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò°¡ 27ÀÏ ´ëÇѾà»çȸ°ü 1Ãþ ´ëȸÀǽǿ¡¼­ °³ÃÖÇÑ ¡®Äڷγª19 Ä¡·áÁ¦ ¹× ¹é½Å °³¹ßÇöȲ°ú ¹é½Å ÃÖÀû ºñÃà±Ô¸ð ÃßÁ¤¡¯À» ÁÖÁ¦·Î ÇÑ 2020³â 1Â÷ Á¤Ã¥Æ÷·³¿¡¼­ ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ÀÓÀ翵 ¿¬±¸Á¶Á¤½ÇÀåÀº À̰°ÀÌ ¹àÇû´Ù.

À̳¯ Æ÷·³¿¡¼­ ÀÓÀ翵 ¿¬±¸Á¶Á¤½ÇÀåÀº ¡®COVID-19 Ä¡·áÁ¦ ¹× ¹é½Å °³¹ß ÇöȲ¡¯ ¹ßÇ¥¸¦ ÅëÇØ ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½ºÀÎ SARS-CoV-2ÀÇ Æ¯Â¡ ¹× ±¸Á¶, °¨¿°±âÀü, Áø´Ü¹æ¹ý, ±¹³»¿Ü ¹ß»ý ÇöȲ, ±¹³»¿Ü Ä¡·áÁ¦ ¹× ¹é½Å °³¹ß »óȲ µîÀ» ÀüÇß´Ù.

ÀÓÀ翵 ½ÇÀåÀº ¡°Äڷγª19´Â Àü ¼¼°èÀû À¯ÇິÀ¸·Î ¹øÁö¸é¼­ Çаè, Á¤ºÎ ¿¬±¸¼Ò, ±ÔÁ¦±â°ü, Á¦¾à»ç, ¹ÙÀÌ¿À±â¾÷µéÀÌ ¿¬±¸°³¹ß, ÀÎÇã°¡ µî ´Ù¾çÇÑ Ãø¸é¿¡¼­ Çù¾÷À» ÅëÇØ Äڷγª19 »çÅÂ ÇØ°áÀ» À§ÇÑ Ä¡·áÁ¦ ¹× ¹é½Å °³¹ß¿¡ ¸ôµÎÇϰí ÀÖÀ¸¸ç, ±× ºñÁî´Ï½º´Â °¡ÆÄ¸£°Ô Ä¿Áö°í ÀÖ´Ù¡±°í ¸»Çß´Ù.

ÀÓ ½ÇÀåÀº ¡°Àü ¼¼°è °³¹ß»ç ¼ö´Â 3¿ù 17ÀÏ ÀÌÈÄ 87%°¡ Áõ°¡Çß°í, 4¿ù 8ÀÏ ±âÁØ 185°³»ç°¡ °³¹ß¿¡ ¶Ù¾îµé¾ú´Ù¡±¸ç ¡°Àü ¼¼°è¿¡¼­ °³¹ßµÇ°í ÀÖ´Â ¾à¹°Àº ¾ÆÁ÷ 80% ÀÌ»óÀÌ ÀÓ»ó ÀÌÀü Ãʱâ´Ü°è¿¡ ÀÖ°í, 30°³ ÀÌ»óÀÇ Å¸±êÀ¸·Î °³¹ßµÇ°í ÀÖ´Ù. µ¿ÀÏÇÑ Å¸±ê¿¡¼­ ¿¬±¸µÇ´Â ¾à¹°ÀÌ ´Ù¼ö Á¸ÀçÇØ ¾à¹°ÀÇ È¿°ú, ¾ÈÀü, ÆíÀ̼ºÀ» ÃæºÐÈ÷ °í·ÁÇØ ºñ±³¿ìÀ§ È®º¸ °úÁ¤ µîÀ» ÅëÇÑ °³¹ßÀÌ ÀÌ·ïÁ®¾ß ÇÑ´Ù¡±°í ¹àÇû´Ù.

±×´Â ¡°È¿À²ÀûÀÎ ¿¬±¸°³¹ßÀ» À§ÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ Áö¿øÀÌ ÇÊ¿äÇÏ¸ç »çȸÀû ÆíÀÍ µîÀ» Á¾ÇÕÀûÀ¸·Î °ËÅäÇØ ÃÖÀû ºñÃà±Ô¸ð¿¡ ´ëÇÑ ³íÀǵµ ÇÊ¿äÇÏ´Ù¡±°í °­Á¶Çß´Ù.

ÀÌ ÀÚ¸®¿¡¼­ ÀÓÀ翵 ½ÇÀåÀº ±ä±Þ»ç¿ëÀÌ ½ÂÀεưųª ÀÓ»ó ÁßÀÎ Äڷγª19 Ä¡·áÁ¦·Î ±æ¸®¾îµå »çÀ̾𽺠Ç×¹ÙÀÌ·¯½ºÁ¦ ¡®·½µ¥½Ãºñ¸£¡¯¸¦ ºñ·ÔÇØ Ç×¹ÙÀÌ·¯½ºÁ¦ ¡®ÇÏÀ̵å·Ï½ÃŬ·Î·ÎÄý¡¯, ÀúÀå È÷¼ø Á¦¾à Ç×¹ÙÀÌ·¯½ºÁ¦ ¡®ÆÄºñÇǶóºñ¸£¡¯, ¸®Á¦³×·Ð¡¤»ç³ëÇÇ ´ÜÀÏŬ·ÐÇ×ü ÀÎÅÍ·çŲ-6 ÀúÇØÁ¦ ¡®»ç¸±·ç¸¿¡¯, À϶óÀÌ ¸±¸® JAK ÀúÇØ ·ù¸¶Æ¼½º Ä¡·áÁ¦ ¡®¹Ù¸®½ÃƼ´Õ¡¯, À϶óÀÌ ¸±¸®, ¾Æ½ºÆ®¶óÁ¦³×Ä«, ¸®Á¦³×·ÐÀÇ Ç×üġ·áÁ¦ µîÀÇ °³¹ß ÁøÇà »óȲ µîÀ» ¹ßÇ¥Çß´Ù.

¿©±â¿¡ Äڷγª19 ¹é½ÅÀ¸·Î °³¹ß ÁßÀÎ ¸ð´õ³ª ¡®mRNA-1273¡¯, Á¸½¼¾ØµåÁ¸½¼ ¡®º¯Çü ¾Æµ¥³ë¹ÙÀÌ·¯½º¡¯, À̳ëºñ¿À ÆÄ¸¶½´Æ¼Äà ¡®INO-4800¡¯, ¿Á½ºÆÛµå´ë ¡®ChAdOx1 nCoV-19¡¯, È­ÀÌÀÚ ¡®BNT162¡¯, »ç³ëÇÇ¡¤GSK ¡®unnamed¡¯, ³ë¹Ù¹é½º ¡®NVX-CoV2373¡¯, Shenzhen Geno-Immune Medical ¡®Lentiviral Minigene Vaccine¡¯ µîÀ» ÇöÀç °³¹ß ´Ü°è ¹× °³¹ß ¿Ï·á ½ÃÁ¡¿¡ ´ëÇØ¼­µµ ¼Ò°³Çß´Ù.

±¹³» °³¹ß »óȲÀ» »ìÆìº¸¸é ¼¿Æ®¸®¿ÂÀÌ S-protein Á¶ÀýÀÚ(modulator) ´ÜÀÏŬ·ÐÇ×ü¿¡ ´ëÇØ ¿Ã 3ºÐ±â ÀÓ»óÀ» ½ÃÀÛÇÒ °èȹÀ̰í, À̹ø޵尡 Ű¸Þ¸¯ Àΰ£È­µÈ ¹ÙÀÌ·¯½º ¾ïÁ¦ÀÎÀÚ(chimeric humanized suppressing factor) ´ÜÀÏÇ×ü·Î Áö³­ 2¿ù Äڷγª19¿¡ ´ëÇÑ ÀüÀÓ»ó´Ü°è¿¡ ÁøÀÔÇß°í, ½Ä¾àó·ÎºÎÅÍ Äڷγª19 ȯÀÚ ´ë»ó ÀÓ»óÀ» ½ÂÀι޾ҴÙ.

¶Ç ÄÚ¹ÌÆÊÀº Àü¸³¼±¾Ï, ºñȣġŲ ¸²ÇÁÁ¾, ³ú¾Ï, ÀüÀ̼º Æó¾Ï µî 11°³ ¾ÏÁ¾¿¡ ´ëÇÑ Ä¡·áÁ¦·Î °³¹ß ÁßÀÎ ÇÕ¼ºÀǾàǰ ¡®KML-001¡¯À» Äڷγª19À» ÀûÀÀÁõÀ¸·Î °³¹ßÇÑ´Ù°í ¹ßÇ¥Çß°í, ºÎ±¤¾àǰÀº Áö³­ 3¿ù Äڷγª19 Ä¡·áÁ¦·Î °³¹ß ÁßÀÎ ¡®Å¬·¹ºÎµò(BÇü °£¿° Ä¡·áÁ¦)¡¯¿¡ ´ëÇØ Áö³­ 3¿ù in vitro ½ÇÇè µ¥ÀÌÅ͸¦ ¹ßÇ¥Çß´Ù.

À̳ëºñ¿ÀÁ¦¾àÀº Áø¿ø»ý¸í°úÇÐ, º£ÀÌ¡ ¾îµå¹é½Å ¹ÙÀÌ¿ÀÅ×Å©³î·ÎÁö¿Í ÇÔ²² ¹Ì±¹, Áß±¹, Çѱ¹¿¡¼­ Äڷγª19 ¹é½Å¿¡ ´ëÇØ °³¹ßÇϰí ÀÖÀ¸·Î ÀüÀÓ»ó ¿¬±¸¸¦ ÁøÇà ÁßÀÌ´Ù. Á¦³Ø½Å°ú ¹ÙÀ̳ؽº´Â Äڷγª19 DNA¹é½Å ¡®GX-19¡¯ °øµ¿°³¹ß »óÈ£ ¾çÇØ°¢¼­¸¦ ü°áÇϰí ÀüÀÓ»ó ´Ü°è °³¹ßÀ» ÁøÇàÇϰí ÀÖ´Ù. SK¹ÙÀÌ¿À»çÀ̾𽺴 Äڷγª19 Èĺ¸¹°ÁúÀ» µµÃâ, Áö³­ 3¿ù 23ÀÏ ÀüÀÓ»ó ´Ü°è °³¹ßÀ» ½ÃÀÛÇß´Ù.



 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
39 [¸Þµð°ÔÀÌÆ®] "Äڷγª19 À¯Çà ³¡³ªµµ ¹é½Å ¿¬±¸°³¹ß °è¼Ó..3000¸¸¸íºÐ ±¹°¡ ºñÃà" ±è¼±Èñ 2020-05-29 1099
38 [¾à¾÷½Å¹®] ¡°Äڷγª19 Ä¡·áÁ¦¡¤¹é½Å, °æÀïÁ¦Ç° ºñ±³¿ìÀ§ È®º¸ Çʼö¡± ±è¼±Èñ 2020-05-29 1138
37 [¾à¾÷½Å¹®] Äڷγª19 ¹é½Å º¸À¯·® Àü ±¹¹Î 52~62% ¼öÁØ µÅ¾ß ±è¼±Èñ 2020-05-29 927
36 [ÄíŰ´º½º] ¡°Äڷγª19 ¹é½Å °³¹ß¡¤ºñÃà, Á¤ºÎ °³ÀÔ ÇʼöÀû¡± ±è¼±Èñ 2020-05-29 795
35 [Àϰ£º¸»ç] ¡®Äڷγª19, Àü ±¹¹Î 60% Á¢Á¾ÇÒ ¹é½Åȯ°æ ±¸ÃàµÅ¾ß¡¯ ±è¼±Èñ 2020-05-29 670
34 [µ¥Àϸ®ÆÊ]"±¹¹Î 60%°¡ ¹é½Å ¸Â¾Æ¾ß Äڷγª19 À¯Çà ¸·´Â´Ù" ±è¼±Èñ 2020-05-29 712
33 [¾à»ç°ø·Ð] ÀǾàǰÁ¤Ã¥¿¬, ¡®Äڷγª19 Ä¡·áÁ¦ ¹× ¹é½Å°³¹ß¡¯ ÁÖÁ¦ Æ÷·³ °³ÃÖ ±è¼±Èñ 2020-05-29 689
32 [´ëÇѾà»çÀú³Î]ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_°í·ÉÈ­¡¤¸¸¼ºÁúȯÀ¸·Î ÀÎÇÑ ÀǾàǰ ¼Òºñ º¯È­ 2 ±è¼±Èñ 2020-05-25 777
31 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_2019³â OECD ÇÑ´«¿¡ º¸´Â °Ç°­(Health at a Glance) 1 ±è¼±Èñ 2020-05-25 877
30 [µ¥Àϸ®ÆÊ] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, Áúº» ¹ßÁÖ ±¹°¡¹é½Å ¿¬±¸ Âü¿© ±è¼±Èñ 2020-05-21 993
29 [º¸°Ç´º½º] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¡®±¹°¡¹é½Å ¼ö±Þ ¸ð´ÏÅ͸µ ¹× ¼ö¿ä ¿¹Ãø ¸ðµ¨¸µ¡¯ »ç¾÷ Âü¿© ±è¼±Èñ 2020-05-21 841
28 [¸ÞµðÆÄ³ª´º½º] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, ±¹°¡¹é½Å ¼ö±Þ ¸ð´ÏÅ͸µ »ç¾÷ Âü¿© ±è¼±Èñ 2020-05-21 699
27 [Àϰ£º¸»ç] ¿ì¸®³ª¶ó ÀǾàǰ ¼Òºñ Áõ°¡À² ¡®ÃÖ»óÀ§¡¯ ±è¼±Èñ 2020-05-15 965
26 [µ¥Àϸ®ÆÊ] Àα¸ 10¸¸¸í´ç ¾à±¹¼ö, OECD Æò±Õº¸´Ù 1.4¹è ³ô¾Æ ±è¼±Èñ 2020-05-15 1196
25 [¸Þµð°ÔÀÌÆ®]¾à±¹ 1ÀÎ °æ¿µ ¹æ½Ä À§ÁÖ.."OECD ´ëºñ ¾à±¹ ¼ö´Â ¸¹Áö¸¸ ¾à»ç´Â Æò±Õ ÀÌÇÏ" ±è¼±Èñ 2020-05-15 788

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»